Amplia CEO and MD, Dr John Lambert, has been interviewed by Proactive Investors regarding plans to trial our FAK inhibitor, AMP945, with newly diagnosed patients receiving first-line therapy for pancreatic cancer.
Dr Lambert clearly outlines why Amplia represents such a strong investment opportunity and the importance of working closely with this patient cohort as part of the upcoming Phase 2 program:
“This is the largest addressable market for a new Pancreatic Cancer drug and because these patients haven’t been through multiple rounds of therapies already, they’re the patients we expect to be most able to respond.”
Click here to take a look.
